title: Expression of IMPDH mRNA after mycophenolate administration in male volunteers.
abstract: BACKGROUND
  Mycophenolic acid (MPA) is the first-line antimetabolic immunosuppressants used in solid organ transplantation. Here, in vivo expressions of the pharmacodynamic marker IMPDH mRNA were analyzed to investigate its usefulness in assessing drug effects.
  
  
  METHODS
  Six healthy male volunteers who had the same genotype for genes known to be associated with drug metabolism and effects were selected to remove the confounding effect of these genotypes. Mycophenolate mofetil (MMF, 1 g) was administered once to each subject, and blood samples were collected with certain interval before and after MMF administration to measure lymphocyte expression levels of IMPDH1 and IMPDH2 mRNA. One week later, the experiment was repeated.
  
  
  RESULTS
  Whereas IMPDH1 mRNA expression was stable, IMPDH2 mRNA expression showed 2 peaks in the first week. Both IMPDH1 and IMPDH2 mRNA expression in the second week remarkably decreased from the first week.
  
  
  CONCLUSIONS
  The temporary increase in IMPDH2 mRNA expression in the first week might be due to a reactive reaction against the plasma MPA concentration. In the second week, the intracellular guanosine monophosphate might be depleted, rendering IMPDH2 mRNA synthesis inactive. When MPA is regularly administered to reach a steady state, the IMPDH2 mRNA expression may be kept low and may effectively reflect biological responses regardless of drug intake.
authors.affiliation: Department of Laboratory Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang 411-706, Republic of Korea.
authors.forename: Sollip
authors.identifier: 0000-0003-0474-5897
authors.initials: S
authors.lastname: Kim
authors.affiliation: Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, 88 Olympic-ro, 43-gil, Songpa-gu, Seoul 138-736, Republic of Korea.
authors.forename: Woochang
authors.identifier: 0000-0003-3956-6397
authors.initials: W
authors.lastname: Lee
authors.affiliation: Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, 88 Olympic-ro, 43-gil, Songpa-gu, Seoul 138-736, Republic of Korea.
authors.forename: Sail
authors.identifier: 0000-0002-5792-973X
authors.initials: S
authors.lastname: Chun
authors.affiliation: Department of Laboratory Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang 411-706, Republic of Korea.
authors.forename: Tae Hyun
authors.identifier: 0000-0003-4879-9408
authors.initials: TH
authors.lastname: Um
authors.affiliation: Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, 88 Olympic-ro, 43-gil, Songpa-gu, Seoul 138-736, Republic of Korea.
authors.forename: Won-Ki
authors.initials: WK
authors.lastname: Min
mesh_terms: D000293:Adolescent; D000328:Adult; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects*; D006801:Humans; D007168:IMP Dehydrogenase / Q000096:biosynthesis*; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D008214:Lymphocytes / Q000166:cytology / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D012333:RNA, Messenger / Q000096:biosynthesis*; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D012333:RNA, Messenger; D007168:IMP Dehydrogenase; C488211:IMPDH1 protein, human; C501687:IMPDH2 protein, human; D009173:Mycophenolic Acid
references.citation: Clin J Am Soc Nephrol. 2010 Feb;5(2):341-58
references.pmid: 20056756
references.citation: Transplant Rev (Orlando). 2008 Jan;22(1):6-20
references.pmid: 18631854
references.citation: Pharmacogenet Genomics. 2010 Sep;20(9):537-43
references.pmid: 20679962
references.citation: Leuk Res. 2008 Jan;32(1):131-41
references.pmid: 17462731
references.citation: Ther Drug Monit. 2009 Oct;31(5):549-56
references.pmid: 19704402
references.citation: Transplant Rev (Orlando). 2011 Apr;25(2):47-57
references.pmid: 21190834
references.citation: Pharmacogenet Genomics. 2009 Aug;19(8):626-34
references.pmid: 19617864
references.citation: Clin Chim Acta. 2001 Aug 1;310(1):81-7
references.pmid: 11485759
references.citation: Transplantation. 2010 Dec 27;90(12):1536-41
references.pmid: 21076373
references.citation: Eur J Clin Pharmacol. 2008 Nov;64(11):1047-56
references.pmid: 18568343
references.citation: Ther Drug Monit. 1997 Apr;19(2):146-52
references.pmid: 9108641
references.citation: Am J Transplant. 2004 Dec;4(12):2045-51
references.pmid: 15575908
references.citation: Am J Transplant. 2009 Nov;9 Suppl 3:S1-155
references.pmid: 19845597
references.citation: Clin Pharmacol Ther. 2008 May;83(5):711-7
references.pmid: 17851563
references.citation: Clin Pharmacol Ther. 1998 Dec;64(6):672-83
references.pmid: 9871432
references.citation: Ther Drug Monit. 2008 Oct;30(5):559-64
references.pmid: 18695635
references.citation: Mol Biol Rep. 2011 Nov;38(8):5185-8
references.pmid: 21181270
references.citation: Br J Clin Pharmacol. 2010 Jan;69(1):38-50
references.pmid: 20078611
references.citation: Ther Drug Monit. 2009 Aug;31(4):416-35
references.pmid: 19536049
references.citation: Transplant Rev (Orlando). 2009 Apr;23(2):120-8
references.pmid: 19298943
references.citation: Ann N Y Acad Sci. 1993 Nov 30;696:63-87
references.pmid: 7906496
references.citation: Immunopharmacology. 2000 May;47(2-3):85-118
references.pmid: 10878285
references.citation: Basic Clin Pharmacol Toxicol. 2010 Aug;107(2):631-6
references.pmid: 20136638
references.citation: Immunopharmacology. 2000 May;47(2-3):163-84
references.pmid: 10878288
references.citation: Hum Mutat. 2006 Jul;27(7):717
references.pmid: 16786511
references.citation: Transplantation. 1999 Jul 27;68(2):261-6
references.pmid: 10440399
references.citation: Kidney Int. 2010 Feb;77(4):299-311
references.pmid: 19847156
references.citation: Transpl Int. 2008 Sep;21(9):879-91
references.pmid: 18444945